ORYZON Initiates Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia
The First Specific LSD1 Inhibitor to Enter the Clinic.
ORYZON, a biopharmaceutical company with a strong focus on epigenetics, has announced that has received the approval from the AEMPS on December 26th, 2013 to initiate a Phase I/IIA clinicaltrial of ORY-1001, a novel and highly selective LSD1 inhibitor, in patients with relapsed or refractory acute leukemia. This first-inhuman trial is currently open at the Hospital Vall d’Hebron in Barcelona, Spain and additional study sites in Spain and in the United Kingdom will be incorporated shortly.
